Guidelines on nicotine dose selection for in vivo research
- S. Matta, D. Balfour, J. Zirger
- Biology, PsychologyPsychopharmacology
- 1 February 2007
A new, experimentally based compilation of species-specific dose selection for studies on the in vivo effects of nicotine, addressing issues related to genetic background, age, acute vs chronic exposure, route of administration, and behavioral responses is provided.
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
- P. Abrams, K. Andersson, A. Wein
- Biology, MedicineBritish Journal of Pharmacology
- 1 July 2006
The evolving understanding of muscarinic receptor functions throughout the body is explored, with particular focus on the bladder, gastrointestinal tract, eye, heart, brain and salivary glands, and the implications for drugs used to treat OAB.
Methods of Behavior Analysis in Neuroscience
- J. Buccafusco
- Biology, Psychology
- 29 August 2000
Transgenic Mouse Models of Alzheimer's Disease: Behavioral Testing and Considerations, K.J. Bryan, H.A. Smith, and G.D. Rosecrans Anxiety-Related Behaviors in Mice, and The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs, J. Buccafusco Index.
The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development
- A. Terry, J. Buccafusco
- Biology, PsychologyJournal of Pharmacology and Experimental…
- 1 September 2003
Cholinergic abnormalities may also contribute to noncognitive behavioral abnormalities as well as the deposition of toxic neuritic plaques in AD and cholinergic-based strategies will likely remain valid as one approach to rational drug development for the treatment of AD other forms of dementia.
Repeated Exposures to Subthreshold Doses of Chlorpyrifos in Rats: Hippocampal Damage, Impaired Axonal Transport, and Deficits in Spatial Learning
- A. Terry, J. Stone, J. Buccafusco, D. W. Sickles, A. Sood, M. Prendergast
- Biology, PsychologyJournal of Pharmacology and Experimental…
- 1 April 2003
Results indicate that repeated exposures to subthreshold doses of CPF may lead to growth retardation, behavioral abnormalities, and muscle weakness, and some of these symptoms may be attributed to effects of the OP on axonal transport.
In Vivo Pharmacological Characterization of a Novel Selective α7 Neuronal Nicotinic Acetylcholine Receptor Agonist ABT-107: Preclinical Considerations in Alzheimer's Disease
- R. Bitner, W. Bunnelle, M. Gopalakrishnan
- Biology, PsychologyJournal of Pharmacology and Experimental…
- 1 September 2010
The findings show that targeting α7 nAChRs may have potential utility for symptomatic alleviation and slowing of disease progression in the treatment of AD, and expand the understanding of the potential therapeutic viability associated with the α7NAChR approach.
Microtubule-associated targets in chlorpyrifos oxon hippocampal neurotoxicity
- M. Prendergast, R. L. Self, A. Terry
- BiologyNeuroscience
- 25 April 2007
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
- M. Youdim, J. Buccafusco
- BiologyTIPS - Trends in Pharmacological Sciences
- 2005
Broad-Spectrum Efficacy across Cognitive Domains by α7 Nicotinic Acetylcholine Receptor Agonism Correlates with Activation of ERK1/2 and CREB Phosphorylation Pathways
- R. Bitner, W. Bunnelle, M. Gopalakrishnan
- Biology, PsychologyJournal of Neuroscience
- 26 September 2007
It is demonstrated that α7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 and CREB phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.
Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides
- S. Mruthinti, J. Buccafusco, R. Schade
- BiologyNeurobiology of Aging
- 1 September 2004
...
...